Results 91 to 100 of about 2,377 (150)

Comparative Therapeutic Strategies for Secondary Progressive Multiple Sclerosis: A Systematic Review and Network Meta-Analysis

Journal of Clinical Question
Introduction: Secondary progressive multiple sclerosis (SPMS) represents a disabling stage of multiple sclerosis with limited treatment options. The evidence regarding the effectiveness of disease-modifying therapies (DMTs) in SPMS remains uncertain ...
Ye Yin, Jinmei Gao, Shahvaiz Magsi, Danyu Zhao   +3 more
doaj   +1 more source

Oral Presentation

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

From pathogenesis and research to the treatment of secondary progressive multiple sclerosis in clinical practice: switching from anti-CD20 monoclonal antibody therapy to siponimod (clinical case)

Неврология, нейропсихиатрия, психосоматика
The pathogenesis of multiple sclerosis is multifaceted and not fully investigated, but it is now clear that each patient has their own ratio of inflammation and neurodegeneration severity.
E. V. Popova
doaj   +1 more source

Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective study

Introduction: Safety concerns have been raised regarding fingolimod to siponimod transition in people with Secondary Progressive Multiple Sclerosis (SPMS). Objective: To explore factors associated with the choice of switching from fingolimod to siponimod
Smolik, Krzysztof, Paola Cavalla, Zanghì, Aurora, Fantozzi, Roberta, Fabiana Marinelli, Schiavetti, Irene, Valentina Scarano, Lavorgna, Luigi, Roberta Fantozzi, Marco Vercellino, Clerico, Marinella, Maria Cellerino, Gina Ferrazzano, Elisabetta Maida, Maida, Elisabetta, Matilde Inglese, Luca Bollo, Pasquali, Livia, De Luca, Giovanna, Giuseppina Miele, Pietro Iaffaldano, Abbadessa, Gianmarco, Marinella Clerico, Landi, Doriana, Irene Schiavetti, Doriana Landi, Emanuele D'Amico, Sormani, Maria Pia, Scarano, Valentina, Simona Bonavita, Trotta, Maria, Vercellino, Marco, Buscarinu, Maria Chiara, Livia Pasquali, Aurora Zanghì, Maria Chiara Buscarinu, Cavalla, Paola, Fabio Buttari, Valentina Torri Clerici, Clerici, Valentina Torri, Miele, Giuseppina, Bonavita, Simona, Iaffaldano, Pietro, Maria Pia Sormani, Tomasso, Ilaria, Gianmarco Abbadessa, Bulgari, Alessandro, Luigi Lavorgna, Bollo, Luca, Cellerino, Maria, Marinelli, Fabiana, Alessandro Bulgari, Alessio Signori, Giovanna De Luca, Ilaria Tomasso, Floriana Bile, Bile, Floriana, Inglese, Matilde, Ferrazzano, Gina, Buttari, Fabio, Signori, Alessio, Maria Trotta, D'Amico, Emanuele, Krzysztof Smolik   +63 more
core   +1 more source

Farmakogenomski pristup liječenju sekundarno progresivne multiple skleroze: fokus na siponimod i CYP2C9

Cilj istraživanja Cilj ovog rada je istražiti i dokumentirati najvažnije spoznaje o učinkovitoj i sigurnoj primjeni siponimoda kod pacijenata koji boluju od sekundarno - progresivne multiple skleroze.
Martinović, Gea
core  

Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data. [PDF]

Front Pharmacol
Wang S, Xie L, Ma P.
europepmc   +1 more source

Retinal neuroprotective function of Siponimod in a mouse model of experimental glaucoma

Objective: To study the protective effects of siponimod on the retina in experimental glaucoma model. Background: Siponimod is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Selective modulation of the sphingosine 1-phosphate
Gupta, V, Basavarajappa, D, Klistorner, A, Chitranshi, N, Graham, S   +4 more
core  

Structural Characterization, Toxicity Assessment and Molecular Modeling of Forced Degradation Products of Siponimod. [PDF]

Int J Mol Sci
Liang Y, Zhang T, Zhang D, Jin B, Ma C.
europepmc   +1 more source